Physician profile
Randall D Staley
NPI 1295918449
$3,345.34
in general payments reported to CMS, 2019-2025
24 companies · $823 in 2025
The $823 reported for 2025 was more than what 83% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $157 · 2021: $166 · 2022: $267 · 2023: $442 · 2024: $721 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,985.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $409.59 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $336.63 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $298.21 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $237.31 | 2019-2025 | Aristada, Lybalvi |
| Corium, LLC | $233.57 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $215.45 | 2019-2025 | Ingrezza |
| Abbvie INC. | $184.19 | 2021-2025 | Vraylar |
| Lundbeck LLC | $151.63 | 2022-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $144.32 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.31 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $127.01 | 2019-2022 | |
| Emd Serono, INC. | $122.99 | 2019 | |
| Axsome Therapeutics, INC. | $120.23 | 2023-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $105.49 | 2019-2020 | |
| Shire North American Group INC | $93.24 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $84.21 | 2022-2024 | Qelbree |
| Sunovion Pharmaceuticals INC. | $80.87 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $64.33 | 2025 | Cobenfy |
| Allergan, INC. | $57.03 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $43.97 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $38.24 | 2023-2024 | Aplenzin, Wellbutrin |
| Vertical Pharmaceuticals, LLC | $35.20 | 2019-2020 | |
| Eisai INC. | $15.86 | 2021 | |
| Alfasigma USA, INC. | $15.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Staley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.